Telix Pharmaceuticals Limited
TLX
Classement en actions
#4434
Telix Pharmaceuticals Limited is an Australian-based radiopharmaceutical... Telix Pharmaceuticals Limited is an Australian-based radiopharmaceutical company dedicated to pioneering molecularly targeted radiation (MTR) products. These innovations are developed for the diagnosis and treatment of various cancers and rare conditions, with its global presence encompassing Australia, Belgium, Japan, Switzerland, and the United States. The company's robust pipeline includes several leading candidates. TLX591-CDx is engineered for the diagnosis and treatment of metastatic castrate-resistant prostate cancer, while TLX66-CDx is designed for bone marrow conditioning and rare diseases. In advanced clinical development, TLX250-CDx is in Phase III trials for renal (kidney) cancer diagnosis and treatment, alongside TLX250 in Phase II for the same indication. TLX591 is also undergoing Phase III trials for metastatic castrate-resistant prostate cancer. For glioblastoma (brain cancer), TLX101 and TLX101-CDx are currently in Phase I/II studies, and TLX66 is in Phase I/IIa trials for bone marrow conditioning and rare diseases. Beyond these flagship programs, Telix is actively developing TLX592, a targeted alpha therapy candidate for prostate cancer. Its portfolio also features TLX591-Sx, a versatile PET tracer capable of both PET and fluorescent (optical) imaging, and TLX599-CDx, an investigational prostate cancer imaging agent utilizing single-photon emission computed tomography (SPECT). Strategic collaborations are integral to Telix's operations. This includes a significant license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for MTR product development, a scientific and clinical research alliance with Mauna Kea Technologies, and a strategic collaboration agreement with Lightpoint Medical, Ltd. Founded in 2015, the company's headquarters are located in North Melbourne, Australia.
Prix de l'action
$10.35
Capitalisation boursière
$3.52B
Changement (1 jour)
0.03%
Changement (1 an)
-5.93%
Pays
AU
Échange Telix Pharmaceuticals Limited (TLX)
Catégorie
Healthcare
Ratio P/E pour Telix Pharmaceuticals Limited (TLX)
Ratio P/E au October 2026 TTM : 109.12
Selon les derniers rapports financiers et le cours de l'action de Telix Pharmaceuticals Limited, le ratio P/E actuel (TTM) est de 109.12. À la fin de l’année 2023, le P/E de l’entreprise était de 617.41.
Historique du ratio P/E pour Telix Pharmaceuticals Limited de 2000 à 2026
Ratio P/E à la fin de chaque année
| Année | Ratio P/E | Changez |
|---|---|---|
| 2026 (TTM) | 109.12 | -33.18% |
| 2024 | 163.29 | -73.55% |
| 2023 | 617.41 | -2,945.40% |
| 2022 | -21.70 | -20.12% |
| 2021 | -27.17 | 25.39% |
| 2020 | -21.67 | 66.86% |
| 2019 | -12.98 | 36.68% |
| 2018 | -9.50 | -27.18% |
| 2017 | -13.05 | -99.42% |
| 2016 | -2.24K | 360.80% |
| 2015 | -486.09 | 711.45% |
| 2000 | -59.90 | 0.00% |
Ratio P/E pour des entreprises similaires ou concurrentes
| Entreprise | P/E Ratio | Différence du P/E Ratio | Pays |
|---|---|---|---|
| 28.78 | -73.62% |
US
|
|
| -28.36 | -125.99% |
US
|
|
| -24.57 | -122.51% |
AU
|
|
| 30.33 | -72.20% |
NL
|
|
| - | - |
CH
|
Comment lire un P/E ratio ?
Le ratio Prix/Bénéfice (P/E Ratio) mesure la relation entre le cours de l'action d'une entreprise et ses bénéfices par action.
Un P/E bas mais positif indique une entreprise qui génère des bénéfices élevés par rapport à sa valorisation et qui pourrait être sous-évaluée. Un P/E négatif élevé (proche de 0) indique des pertes importantes.
Les entreprises avec un P/E supérieur à 30 ou négatif sont généralement considérées comme des "actions de croissance", ce qui signifie que les investisseurs s'attendent à ce qu'elles se développent ou deviennent rentables.
Les entreprises avec un P/E positif inférieur à 10 sont généralement considérées comme des "actions de valeur", car elles sont déjà très rentables mais avec peu de potentiel de croissance.